2026 Innovation Issue: Building on a brother’s legacy

May 1, 2026 - 17:45

The late Philip Low dedicated his scientific career to a singular, ambitious goal: using small molecules to precisely target and deliver treatments directly to cancer cells. His work, which spanned decades, laid the groundwork for a new class of therapies that could potentially reduce the harsh side effects of traditional chemotherapy. Now, his brother Martin Low is tasked with carrying that vision forward.

In a recent conversation, Martin reflected on the science that defined his brother's life. Philip's approach focused on identifying unique receptors found on the surface of cancer cells, then designing small molecules that could bind to those receptors like a key in a lock. This allowed therapeutic agents to be hitched to those molecules, creating a guided missile system of sorts. The goal was to make cancer treatment more precise and less damaging to healthy tissue.

Martin Low discussed where the company founded on these principles is headed. He emphasized that the core research remains the foundation, but the focus is now on moving these discoveries from the lab bench to the patient bedside. The path forward involves refining the delivery systems, expanding the types of cancers that can be targeted, and navigating the complex regulatory landscape. While the loss of his brother is profound, Martin made it clear that the mission is far from over. The work continues, driven by the same relentless curiosity and determination that defined Philip's legacy.